Physician profile
Benjamin Aronbayev
NPI 1265024525
$6,616.23
in general payments reported to CMS, 2019-2025
25 companies · $2,509 in 2025
The $2,509 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $317 · 2022: $1,197 · 2023: $1,046 · 2024: $1,548 · 2025: $2,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,004 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,003.91 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,477.78 | 2021-2025 | |
| Janssen Biotech, INC. | $905.07 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $563.73 | 2021-2025 | Xifaxan, Plenvu |
| Ardelyx, INC. | $350.23 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $326.08 | 2023-2025 | Voquezna |
| Gilead Sciences, INC. | $306.25 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $305.20 | 2023-2025 | Entyvio, Livtencity, Gattex |
| Genzyme Corporation | $197.86 | 2021-2025 | |
| Intra-Sana Laboratories | $193.70 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Intercept Pharmaceuticals, INC. | $175.68 | 2021-2024 | Ocaliva |
| Pfizer INC. | $163.59 | 2023-2025 | |
| Madrigal Pharmaceuticals | $149.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $75.97 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $57.07 | 2022-2023 | Dupixent |
| Redhill Biopharma INC. | $45.96 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $45.56 | 2025 | Vegzelma |
| Incyte Corporation | $42.24 | 2023 | Opzelura |
| Janssen Scientific Affairs, LLC | $40.50 | 2024 | Stelara |
| Lilly USA, LLC | $39.78 | 2023-2024 | Taltz |
| Ipsen Biopharmaceuticals, INC | $37.62 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $35.12 | 2024-2025 | Suflave, Sutab |
| Celgene Corporation | $32.29 | 2022-2023 | Zeposia |
| Vyne Pharmaceuticals INC. | $18.22 | 2021 | |
| Exact Sciences Corporation | $16.62 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $14.72 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Aronbayev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.